Journal article
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Abstract
BACKGROUND: Angiotensin-converting-enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients.
Authors
Pfeffer MA; McMurray JJV; Velazquez EJ; Rouleau J-L; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H
Journal
New England Journal of Medicine, Vol. 349, No. 20, pp. 1893–1906
Publisher
Massachusetts Medical Society
Publication Date
November 13, 2003
DOI
10.1056/nejmoa032292
ISSN
0028-4793